2015
The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States
Durham DP, Skrip LA, Bruce RD, Vilarinho S, Elbasha EH, Galvani AP, Townsend JP. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States. Clinical Infectious Diseases 2015, 62: 298-304. PMID: 26628566, PMCID: PMC4706637, DOI: 10.1093/cid/civ894.Peer-Reviewed Original ResearchConceptsHepatitis C virusInterferon-free DAAsHCV incidenceTreatment ratesChronic hepatitis C virusCases of cirrhosisInjection drug useImpact of administrationAnnual treatment ratesEnhanced screeningHCV prevalenceHCV screeningDecompensated cirrhosisHCV infectionHCV transmissionHepatitis CLiver transplantActing antiviralsLevels of screeningPatients 4C virusHepatocellular carcinomaEpidemiological dataUniversal screeningDrug use
2010
Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low?
Bauch CT, Li M, Chapman G, Galvani AP. Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low? The Lancet Infectious Diseases 2010, 10: 133-137. PMID: 20113982, DOI: 10.1016/s1473-3099(10)70004-9.Peer-Reviewed Original ResearchConceptsCervical cancerVaccinated womenVaccine coverageEffective cervical screening programmesHuman papillomavirus vaccinationCervical screening programmeHigh-risk typesIntroduction of vaccinesPapillomavirus vaccinationOncogenic typesCervical screeningOpportunistic screeningScreening programPrevents infectionCancerVaccineIncidenceContinued screeningWomenVaccinationScreeningPopulationDisease incidenceInfection